Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Managed care considerations.

Jeffrey D Dunn1

  • 1SelectHealth, 9502 Carriage Chase Ln, Sandy, UT 04092, USA. jeffrey.dunn@selecthealth.org

The American Journal of Managed Care
|July 18, 2008
PubMed
Summary
This summary is machine-generated.

Antiplatelet therapy, including aspirin and aspirin plus extended-release dipyridamole, is recommended for secondary stroke prevention. These treatments are cost-effective for patients with mild ischemic stroke or TIA, reducing recurrence risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.

Diabetes, obesity & metabolism·2025
Same author

Transforming retinal disease management through diabetes care.

Journal of managed care & specialty pharmacy·2025
Same author

Glycogen Storage Disease Type Ia: A Retrospective Claims Analysis of Complications, Resource Utilization, and Cost of Care.

Journal of health economics and outcomes research·2025
Same author

Evolving knowledge of the unmet needs in dry eye disease.

The American journal of managed care·2021
Same author

Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.

PharmacoEconomics·2019
Same author

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.

PharmacoEconomics·2018
Same journal

Prescription drug prior authorization: costs to pharmacies and physicians.

The American journal of managed care·2026
Same journal

Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

The American journal of managed care·2026
Same journal

The societal costs of food insecurity: implications for managed care strategies.

The American journal of managed care·2026
Same journal

Availability of hospital financial assistance documents in non-English languages.

The American journal of managed care·2026
Same journal

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

The American journal of managed care·2026
Same journal

Social needs screening and supplemental benefits in Medicare Advantage.

The American journal of managed care·2026
See all related articles

Area of Science:

  • Neurology
  • Pharmacoeconomics
  • Cardiovascular Medicine

Background:

  • Stroke is a leading cause of death and disability in the US, with ischemic strokes being the most common type.
  • Transient ischemic attacks (TIAs) often precede strokes, and patients face a high risk of recurrent events, increasing disability and costs.
  • Secondary prevention is crucial for stroke survivors to mitigate impairment and reduce healthcare expenditures.

Purpose of the Study:

  • To discuss the burden of stroke on patients and caregivers.
  • To review the risk of stroke recurrence and the role of antiplatelet therapy in secondary prevention.
  • To analyze the pharmacoeconomics of antiplatelet agents for secondary stroke prevention.

Main Methods:

  • Review of current guidelines for secondary stroke prevention, including recommendations from the American Heart Association/American Stroke Association.

Related Experiment Videos

  • Analysis of clinical outcomes associated with antiplatelet therapy in patients with TIA or prior ischemic stroke.
  • Pharmacoeconomic evaluation of aspirin (ASA), ASA + extended-release dipyridamole (DP), and clopidogrel.

    • Main Results:

    • Updated guidelines recommend antiplatelet agents over anticoagulants for secondary prevention in ischemic noncardioembolic stroke or TIA.
    • ASA, ASA + DP, and clopidogrel are identified as acceptable initial treatment options.
    • Pharmacoeconomic analysis indicates that ASA and ASA + DP are cost-effective for secondary prevention in patients with mild initial strokes.

    Conclusions:

    • Effective secondary prevention with antiplatelet therapy can improve clinical outcomes and reduce the risk of recurrent stroke.
    • ASA and ASA + DP represent cost-effective options for secondary stroke prevention, particularly for mild initial events.
    • Optimizing antiplatelet therapy use can enhance clinical and economic outcomes, lessening the overall burden of cerebrovascular disease.